Lv54
1410 积分 2022-11-21 加入
HER2阳性乳腺癌治疗的研究进展
1天前
待确认
In-depth characterization of a cysteine-linked ADC disitamab vedotin by multiple LC-MS analysis methods and cutting-edge imaged capillary isoelectric focusing coupled with native mass spectrometry
14天前
已完结
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
14天前
已完结
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
1个月前
已完结
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
In-depth characterization of a cysteine-linked ADC disitamab vedotin by multiple LC-MS analysis methods and cutting-edge imaged capillary isoelectric focusing coupled with native mass spectrometry
1个月前
已完结
P2.10.12 Trastuzumab Deruxtecan in Patients From China With Pretreated HER2-Mutant NSCLC: Final Results From the DESTINY-Lung05 Study
1个月前
已完结
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
1个月前
已完结
Ocular Adverse Events Associated with Antibody–Drug Conjugates in Human Clinical Trials
1个月前
已完结
American Society of Breast Surgeons and Society of Breast Imaging 2025 Guidelines for the Management of Benign Breast Fibroepithelial Lesions
1个月前
已完结
皖公网安备34019202002308
